Tag Archives: EGFR mutation
Dr. Lecia Sequist (Pt. 2): Post-ASCO Debrief & Efforts with IASLC
Dr. Lecia Sequist (Pt. 1): Combining Interests in Science and Practical Issues in Cancer Care
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter. (13:27)
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and whether this positive trial changes management in this setting. (9:58)
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III NSCLC and highlights new data on overall survival and the different results in patient subgroups. (7:21)
Is Chemo the Key to the Best Combination for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook (BMIC-045)
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy in patients with EGFR mutation-positive advanced NSCLC. (12:37)
Is the Survival Benefit from Dacomitinib on the ARCHER-1050 Trial Enough to Make it a Contender as First Line Treatment for EGFR Mutation-Positive NSCLC Today? (BMIC-044)
Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positive NSCLC, asks whether the demonstrated survival benefit is enough to make dacomitinib a player as first line treatment. (7:04)
The Erlotinib/Bevacizumab Combination in EGFR Mutation-Positive Advanced NSCLC: Is Progression-Free Survival without Overall Survival Benefit Enough? (BMIC-043)
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva) with bevacizumab (Avastin), which shows a consistent improvement in progression-free survival but not overall survival. (10:15)
Small Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042)
Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR mutation-positive patients with high tumor PD-L1 expression, which led to poor outcomes that should cast a long shadow on this approach. (7:11)